432 related articles for article (PubMed ID: 29969654)
21. Appearance of tissue transglutaminase in astrocytes in multiple sclerosis lesions: a role in cell adhesion and migration?
van Strien ME; Drukarch B; Bol JG; van der Valk P; van Horssen J; Gerritsen WH; Breve JJ; van Dam AM
Brain Pathol; 2011 Jan; 21(1):44-54. PubMed ID: 20731658
[TBL] [Abstract][Full Text] [Related]
22. Transglutaminase 2 protects against ischemic stroke.
Filiano AJ; Tucholski J; Dolan PJ; Colak G; Johnson GV
Neurobiol Dis; 2010 Sep; 39(3):334-43. PubMed ID: 20451610
[TBL] [Abstract][Full Text] [Related]
23. Transglutaminase 2 promotes PDGF-mediated activation of PDGFR/Akt1 and β-catenin signaling in vascular smooth muscle cells and supports neointima formation.
Nurminskaya M; Beazley KE; Smith EP; Belkin AM
J Vasc Res; 2014; 51(6):418-28. PubMed ID: 25612735
[TBL] [Abstract][Full Text] [Related]
24. Cytosolic guanine nucledotide binding deficient form of transglutaminase 2 (R580a) potentiates cell death in oxygen glucose deprivation.
Colak G; Keillor JW; Johnson GV
PLoS One; 2011 Jan; 6(1):e16665. PubMed ID: 21304968
[TBL] [Abstract][Full Text] [Related]
25. Tissue transglutaminase activity is involved in the differentiation of oligodendrocyte precursor cells into myelin-forming oligodendrocytes during CNS remyelination.
Van Strien ME; Baron W; Bakker EN; Bauer J; Bol JG; Brevé JJ; Binnekade R; Van Der Laarse WJ; Drukarch B; Van Dam AM
Glia; 2011 Nov; 59(11):1622-34. PubMed ID: 21818782
[TBL] [Abstract][Full Text] [Related]
26. Mapping the minimum domain of the fibronectin binding site on transglutaminase 2 (TG2) and its importance in mediating signaling, adhesion, and migration in TG2-expressing cells.
Soluri MF; Boccafoschi F; Cotella D; Moro L; Forestieri G; Autiero I; Cavallo L; Oliva R; Griffin M; Wang Z; Santoro C; Sblattero D
FASEB J; 2019 Feb; 33(2):2327-2342. PubMed ID: 30285580
[TBL] [Abstract][Full Text] [Related]
27. Transglutaminase 2 strongly binds to an extracellular matrix component other than fibronectin via its second C-terminal beta-barrel domain.
Stamnaes J; Cardoso I; Iversen R; Sollid LM
FEBS J; 2016 Nov; 283(21):3994-4010. PubMed ID: 27685605
[TBL] [Abstract][Full Text] [Related]
28. Injury-induced "switch" from GTP-regulated to novel GTP-independent isoform of tissue transglutaminase in the rat spinal cord.
Festoff BW; SantaCruz K; Arnold PM; Sebastian CT; Davies PJ; Citron BA
J Neurochem; 2002 May; 81(4):708-18. PubMed ID: 12065630
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of HMGB1 reduces rat spinal cord astrocytic swelling and AQP4 expression after oxygen-glucose deprivation and reoxygenation via TLR4 and NF-κB signaling in an IL-6-dependent manner.
Sun L; Li M; Ma X; Feng H; Song J; Lv C; He Y
J Neuroinflammation; 2017 Nov; 14(1):231. PubMed ID: 29178911
[TBL] [Abstract][Full Text] [Related]
30. Intimal hyperplasia in loop-injured carotid arteries is attenuated in transglutaminase 2-null mice.
Min SK; Min SI; Jeong EM; Cho SY; Ha J; Kim SJ; Kim IG
J Korean Med Sci; 2014 Mar; 29(3):363-9. PubMed ID: 24616585
[TBL] [Abstract][Full Text] [Related]
31. Transglutaminase 2 is central to induction of the arterial calcification program by smooth muscle cells.
Johnson KA; Polewski M; Terkeltaub RA
Circ Res; 2008 Mar; 102(5):529-37. PubMed ID: 18202319
[TBL] [Abstract][Full Text] [Related]
32. Glial scar and axonal regeneration in the CNS: lessons from GFAP and vimentin transgenic mice.
Ribotta MG; Menet V; Privat A
Acta Neurochir Suppl; 2004; 89():87-92. PubMed ID: 15335106
[TBL] [Abstract][Full Text] [Related]
33. Role of transglutaminase 2 in A
Vyas FS; Nelson CP; Dickenson JM
Eur J Pharmacol; 2018 Jan; 819():144-160. PubMed ID: 29208472
[TBL] [Abstract][Full Text] [Related]
34. Tumor Necrosis Factor-stimulated Gene-6 (TSG-6) Is Constitutively Expressed in Adult Central Nervous System (CNS) and Associated with Astrocyte-mediated Glial Scar Formation following Spinal Cord Injury.
Coulson-Thomas VJ; Lauer ME; Soleman S; Zhao C; Hascall VC; Day AJ; Fawcett JW
J Biol Chem; 2016 Sep; 291(38):19939-52. PubMed ID: 27435674
[TBL] [Abstract][Full Text] [Related]
35. Impact of neural cell adhesion molecule deletion on regeneration after mouse spinal cord injury.
Saini V; Loers G; Kaur G; Schachner M; Jakovcevski I
Eur J Neurosci; 2016 Jul; 44(1):1734-46. PubMed ID: 27178448
[TBL] [Abstract][Full Text] [Related]
36. Transglutaminase Type 2 regulates the Wnt/β-catenin pathway in vertebrates.
Rossin F; Costa R; Bordi M; D'Eletto M; Occhigrossi L; Farrace MG; Barlev N; Ciccosanti F; Muccioli S; Chieregato L; Szabo I; Fimia GM; Piacentini M; Leanza L
Cell Death Dis; 2021 Mar; 12(3):249. PubMed ID: 33674551
[TBL] [Abstract][Full Text] [Related]
37. Transglutaminase 2 suppresses apoptosis by modulating caspase 3 and NF-kappaB activity in hypoxic tumor cells.
Jang GY; Jeon JH; Cho SY; Shin DM; Kim CW; Jeong EM; Bae HC; Kim TW; Lee SH; Choi Y; Lee DS; Park SC; Kim IG
Oncogene; 2010 Jan; 29(3):356-67. PubMed ID: 19838207
[TBL] [Abstract][Full Text] [Related]
38. Intracellular localization and conformational state of transglutaminase 2: implications for cell death.
Gundemir S; Johnson GV
PLoS One; 2009 Jul; 4(7):e6123. PubMed ID: 19568436
[TBL] [Abstract][Full Text] [Related]
39. Transglutaminase 2 as a therapeutic target for neurological conditions.
Keillor JW; Johnson GVW
Expert Opin Ther Targets; 2021 Sep; 25(9):721-731. PubMed ID: 34607527
[TBL] [Abstract][Full Text] [Related]
40. CHIP-mediated degradation of transglutaminase 2 negatively regulates tumor growth and angiogenesis in renal cancer.
Min B; Park H; Lee S; Li Y; Choi JM; Lee JY; Kim J; Choi YD; Kwon YG; Lee HW; Bae SC; Yun CO; Chung KC
Oncogene; 2016 Jul; 35(28):3718-28. PubMed ID: 26568304
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
